The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

PLA2G7  -  phospholipase A2, group VII (platelet...

Homo sapiens

Synonyms: 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycerophosphocholine esterase, Group-VIIA phospholipase A2, LDL-PLA(2), LDL-PLA2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PLA2G7


High impact information on PLA2G7


Chemical compound and disease context of PLA2G7


Biological context of PLA2G7

  • The plasma PAFAH gene (PLA2G7) is located on chromosome 6p [16].
  • We investigated the association of the PLA2G7 A379V variant with changes in body composition in a longitudinal study of 123 male Caucasian army recruits over 10 weeks of intensive physical training [17].
  • Our aim was to look for further PAFAH variants in white populations, their possible association with atopic and asthmatic phenotypes, and their functional importance [18].
  • Its gamma-subunit (which, formerly, we called the 29-kDa subunit) acts as a catalytic subunit, whereas the alpha-subunit (45 kDa) is the bovine homolog of the product of human LIS-1, the causative gene of Miller-Dieker lissencephaly, indicating that this intracellular PAF acetylhydrolase plays a key role in brain development [2].
  • Plasma PAF acetylhydrolase activity was higher in patients than in control subjects, in normal subjects, or patients with a heterozygous genotype [19].

Anatomical context of PLA2G7


Associations of PLA2G7 with chemical compounds


Physical interactions of PLA2G7


Regulatory relationships of PLA2G7

  • We show evidence that both PAF acetylhydrolase (PAF-AH) and transacetylase activities are inhibited to the same extent by serine esterase inhibitors, are resistant to heat treatment, and exhibit identical distributions in lipoprotein classes and in LDL subfractions [28].
  • These results indicate the PAF acetylhydrolase gene mutation may influence the degree of proteinuria and the extent of mesangial proliferation in the early stage of childhood IgA nephropathy [29].

Other interactions of PLA2G7

  • The aim of this study was to relate the variability of the genes encoding PAF-AH (PLA2G7) and the PAF-receptor (PTAFR) to the risk of CAD and its complications [30].
  • We conclude that PAF acetylhydrolase is the sole phospholipase A(2) of HDL and that PON1 has no phospholipase activity toward PAF or pro-atherogenic oxidized phospholipids [31].
  • PAF acetylhydrolase, an oxidized phospholipid phospholipase A(2), is a serine esterase associated with specific HDL particles [31].
  • The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma [18].
  • TNF-alpha-mediated neuronal apoptosis can also be blocked by co-incubation with PAF acetylhydrolase, or a PAF receptor antagonist [22].

Analytical, diagnostic and therapeutic context of PLA2G7


  1. Platelet-activating factor and human meningiomas. Denizot, Y., De Armas, R., Caire, F., Pommepuy, I., Truffinet, V., Labrousse, F. Neuropathol. Appl. Neurobiol. (2006) [Pubmed]
  2. Cloning and expression of a cDNA encoding the beta-subunit (30-kDa subunit) of bovine brain platelet-activating factor acetylhydrolase. Hattori, M., Adachi, H., Aoki, J., Tsujimoto, M., Arai, H., Inoue, K. J. Biol. Chem. (1995) [Pubmed]
  3. A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Yoshida, H., Imaizumi, T., Fujimoto, K., Itaya, H., Hiramoto, M., Yoshimizu, N., Fukushi, K., Satoh, K. Thromb. Haemost. (1998) [Pubmed]
  4. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation. Yamada, Y., Yokota, M. Biochem. Biophys. Res. Commun. (1997) [Pubmed]
  5. Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Yamada, Y., Ichihara, S., Fujimura, T., Yokota, M. Metab. Clin. Exp. (1998) [Pubmed]
  6. Miller-Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase [corrected]. Hattori, M., Adachi, H., Tsujimoto, M., Arai, H., Inoue, K. Nature (1994) [Pubmed]
  7. Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases. Camussi, G., Tetta, C., Bussolino, F., Baglioni, C. J. Exp. Med. (1988) [Pubmed]
  8. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. Stafforini, D.M., Numao, T., Tsodikov, A., Vaitkus, D., Fukuda, T., Watanabe, N., Fueki, N., McIntyre, T.M., Zimmerman, G.A., Makino, S., Prescott, S.M. J. Clin. Invest. (1999) [Pubmed]
  9. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. Stafforini, D.M., Satoh, K., Atkinson, D.L., Tjoelker, L.W., Eberhardt, C., Yoshida, H., Imaizumi, T., Takamatsu, S., Zimmerman, G.A., McIntyre, T.M., Gray, P.W., Prescott, S.M. J. Clin. Invest. (1996) [Pubmed]
  10. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. Ambrosio, G., Oriente, A., Napoli, C., Palumbo, G., Chiariello, P., Marone, G., Condorelli, M., Chiariello, M., Triggiani, M. J. Clin. Invest. (1994) [Pubmed]
  11. Relationships between plasma levels of type-II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1, and thrombomodulin in patients with sepsis. Takakuwa, T., Endo, S., Nakae, H., Suzuki, T., Inada, K., Yoshida, M., Ogawa, M., Uchida, K. Res. Commun. Chem. Pathol. Pharmacol. (1994) [Pubmed]
  12. Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. Tsukioka, K., Matsuzaki, M., Nakamata, M., Kayahara, H., Nakagawa, T. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología. (1996) [Pubmed]
  13. PAF acetylhydrolase and arachidonic acid metabolite levels in patients with sepsis. Takakuwa, T., Endo, S., Nakae, H., Kikichi, M., Inada, K., Yoshida, M. Res. Commun. Chem. Pathol. Pharmacol. (1994) [Pubmed]
  14. Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock. Nakae, H., Endo, S., Inada, K., Yaegashi, Y., Takakuwa, T., Yamada, Y., Arakawa, N., Suzuki, T., Taniguchi, S., Shimamura, T., Ogawa, M., Teraoka, H. Res. Commun. Mol. Pathol. Pharmacol. (1996) [Pubmed]
  15. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Izaki, S., Yamamoto, T., Goto, Y., Ishimaru, S., Yudate, F., Kitamura, K., Matsuzaki, M. Br. J. Dermatol. (1996) [Pubmed]
  16. Lack of evidence for associations between plasma platelet-activating factor acetylhydrolase deficiency and schizophrenia. Ohtsuki, T., Watanabe, H., Toru, M., Arinami, T. Psychiatry research. (2002) [Pubmed]
  17. Lipoprotein-associated phospholipase A2 A379V variant is associated with body composition changes in response to exercise training. Wootton, P.T., Flavell, D.M., Montgomery, H.E., World, M., Humphries, S.E., Talmud, P.J. Nutrition, metabolism, and cardiovascular diseases : NMCD (2007) [Pubmed]
  18. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Kruse, S., Mao, X.Q., Heinzmann, A., Blattmann, S., Roberts, M.H., Braun, S., Gao, P.S., Forster, J., Kuehr, J., Hopkin, J.M., Shirakawa, T., Deichmann, K.A. Am. J. Hum. Genet. (2000) [Pubmed]
  19. A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke. Hiramoto, M., Yoshida, H., Imaizumi, T., Yoshimizu, N., Satoh, K. Stroke (1997) [Pubmed]
  20. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. Howard, K.M., Olson, M.S. J. Biol. Chem. (2000) [Pubmed]
  21. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. Patel, K.D., Zimmerman, G.A., Prescott, S.M., McIntyre, T.M. J. Biol. Chem. (1992) [Pubmed]
  22. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. Perry, S.W., Hamilton, J.A., Tjoelker, L.W., Dbaibo, G., Dzenko, K.A., Epstein, L.G., Hannun, Y., Whittaker, J.S., Dewhurst, S., Gelbard, H.A. J. Biol. Chem. (1998) [Pubmed]
  23. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Tew, D.G., Southan, C., Rice, S.Q., Lawrence, M.P., Li, H., Boyd, H.F., Moores, K., Gloger, I.S., Macphee, C.H. Arterioscler. Thromb. Vasc. Biol. (1996) [Pubmed]
  24. PAF analogues capable of inhibiting PAF acetylhydrolase activity suppress migration of isolated rat cerebellar granule cells. Adachi, T., Aoki, J., Manya, H., Asou, H., Arai, H., Inoue, K. Neurosci. Lett. (1997) [Pubmed]
  25. Metabolism and effect of platelet-activating factor on the growth of human myeloma cell lines. Desplat, V., Dulery, C., Faucher, J.L., Praloran, V., Denizot, Y. Cancer Lett. (2000) [Pubmed]
  26. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. Satoh, K., Imaizumi, T., Kawamura, Y., Yoshida, H., Hiramoto, M., Takamatsu, S., Takamatsu, M. J. Clin. Invest. (1991) [Pubmed]
  27. The contribution of individual lipoproteins to the degradation of platelet-activating factor in human serum. Ostermann, G., Kostner, G.M., Gries, A., Malle, E., Till, U. Haemostasis (1989) [Pubmed]
  28. Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein. Tsoukatos, D.C., Liapikos, T.A., Tselepis, A.D., Chapman, M.J., Ninio, E. Biochem. J. (2001) [Pubmed]
  29. Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. Tanaka, R., Iijima, K., Xu, H., Inoue, Y., Murakami, R., Shirakawa, T., Nishiyama, K., Miwa, M., Shiozawa, S., Nakamura, H., Yoshikawa, N. Am. J. Kidney Dis. (1999) [Pubmed]
  30. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Ninio, E., Tregouet, D., Carrier, J.L., Stengel, D., Bickel, C., Perret, C., Rupprecht, H.J., Cambien, F., Blankenberg, S., Tiret, L. Hum. Mol. Genet. (2004) [Pubmed]
  31. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. Marathe, G.K., Zimmerman, G.A., McIntyre, T.M. J. Biol. Chem. (2003) [Pubmed]
  32. Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. Montrucchio, G., Bergerone, S., Bussolino, F., Alloatti, G., Silvestro, L., Lupia, E., Cravetto, A., Di Leo, M., Emanuelli, G., Camussi, G. Circulation (1993) [Pubmed]
  33. Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation. Androulakis, N., Durand, H., Ninio, E., Tsoukatos, D.C. J. Lipid Res. (2005) [Pubmed]
WikiGenes - Universities